Dexing Zeng, Ph.D.

  • Associate Professor of Diagnostic Radiology, School of Medicine
  • Director of Organic Chemistry, Center for Radiochemistry Research, School of Medicine


Dexing Zeng is an assistant professor in the Department of Diagnostic Radiology at Oregon Health & Science University and the Director of Organic Chemistry in the Center for Radiochemistry Research (CRR) in the Knight Cardiovascular Institute. Dr. Zeng received his PhD in organic chemistry from the Chinese Academy of Sciences in Beijing. After 3 years postdoc training in developing stable-isotope enriched agents for proteomics studies, he continued his training in radiochemistry at the Mallinckrodt Institute of Radiology in the Washington University School of Medicine. In 2011, Dr. Zeng was recruited by the University of Pittsburgh as a new faculty member, focusing on development of novel chemistry for PET imaging. In 2018, he moved to Oregon and joined OHSU Department of Diagnostic Radiology.

Dr. Zeng’s research focuses on PET imaging and receptor-targeted radionuclide therapy, utilizing the newly developed Sequential Multi-Agent Receptor Targeting (SMART) technology. By synergizing the advantages from both mAb (long tumor-retention) and peptide (fast non- tumor-clearing), this novel SMART strategy provides substantially enhanced tumor uptakes, and significantly reduced non-tumor uptakes, and thus greatly facilitates cancer theranostic. Additionally, Dr. Zeng has explored its applications in tumor microenvironment characterization, HIV reservoir imaging, and PET imaging of other infection diseases.


  • B.S., 2000, Chemistry, Harbin Engineering University
  • Ph.D., 2005, Organic Chemistry, Chinese Academy of Sciences

Memberships and associations

  • American Chemical Society
  • Society of Nuclear Medicine
  • International Society of Radiopharmaceutical Sciences
  • World Molecular Imaging Society

Areas of interest

  • Cancer imaging and early detection
  • Tumor microenvironment characterization
  • Imaging-guided therapy
  • Receptor-targeted Radionuclide therapy
  • Combining radiotherapy with molecular targeting and immunomodulatory agents



  • “{{ pub.title }}” {{ pub.journalAssociation.journal.names[0].value }}